Poxel

Developing Innovative Drugs for Metabolic Diseases

Lyon, France · Founded 2009 · $33.8M raised

Headquarters
Lyon
Employees
11–50
Founded
2009
Business Model
B2B
Total Funding
$33.8M
Last Round
$15.2M Series BDec 2012
Rounds
2

Totals include recorded grants and other qualifying funding, not just equity. What counts toward funding.

About

Poxel is a clinical-stage biopharmaceutical company developing innovative treatments for chronic and rare diseases with metabolic pathophysiology. Founded in 2009 as a spin-off from Merck Serono in Lyon, France, the company focuses on non-alcoholic steatohepatitis (NASH) and rare metabolic disorders. Its lead programs include PXL065 (NASH), PXL770 (rare diseases including ALD and ADPKD), and Imeglimin (Twymeeg), a first-in-class treatment for type 2 diabetes approved in Japan in 2021 and commercialized by partner Sumitomo Pharma across Asia. Poxel's AMPK-activator and deuterium-modified thiazolidinedione (dTZD) platforms target mitochondrial dysfunction and cellular energy metabolism.

Summary

Poxel is a Biotech company based in Lyon, France, founded in 2009. It has raised $33.8M in total across 2 rounds, most recently a $15.2M Series B round in Dec 2012. Investors include Edmond de Rothschild Investment Partners and Omnes Capital.

Tech & App Stack

1 technology or app tracked

Every product and vendor across these categories, with where each signal came from.

Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.

Funding History

Series BSeries BDec 2012
$15.2M

Sign up to see all 2 events

Funding: Series A through Series B. Amounts, valuations, and investors where available.

Investors

Similar Companies

Pharmaceutical Product Development, Inc. (PPD)Acquired

Global contract research organization providing comprehensive drug development and laboratory ser...

Wilmington, United States10001+Biotech, Healthcare
Private EquityTotal funding$3.9BJan 2019
Warner ChilcottAcquired

Specialty pharmaceutical company

Rockaway, United States1001–5000Biotech, Healthcare
Private EquityTotal funding$3.0BJan 2004
Altos Labs

Altos Labs combines academic science and industry development to create medicines that restore ce...

San Francisco, United States501–1000Life Sciences, Biotech
Series ATotal funding$3.0BJan 2022
Syneos HealthAcquired

Integrated biopharmaceutical solutions company

Burlington, United States10001+Biotech, Healthcare
Private EquityTotal funding$3.0BMay 2017
BeiGeneIPO

BeOne Medicines develops transformative oncology medicines through rigorous science, an accelerat...

Cambridge, United States10001+Biotech, Oncology
Corporate RoundTotal funding$2.8BJan 2020
BridgeBioIPO

BridgeBio develops treatments for genetic conditions through autonomous condition-focused teams s...

San Francisco Bay Area, United States201–500Biotech, Healthcare
Growth EquityTotal funding$2.7BJul 2026

Your company? Embed this profile

Add the live badge to your site — it stays current as your funding data updates.

Poxel on Indexed.vc
<a href="https://indexed.vc/companies/poxel"><img src="https://indexed.vc/api/badge/company/poxel" alt="Poxel on Indexed.vc" width="260" height="76" /></a>